BrainStorm Cell Therapeutics Secures Funding for ALS Clinical Trials

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that the company has secured the funding required to complete pre-clinical trials underway for the treatment of ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease) The company expects to begin Phase I clinical studies in 2010.

Click here to read more.

Share this: